Status:
COMPLETED
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Centers for Disease Control and Prevention
Astellas Pharma Inc
Conditions:
Covid19
Aspergillosis
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to identify the number of individuals with severe CoVID who require ventilator support and who develop serious fungal infections. The study is an observational study, mean...
Detailed Description
COVID-19 is a disease caused by infection with the novel coronavirus SARS-COV2 which emerged in late 2019 in Wuhan, China (1). This illness is associated with viral prodromal symptoms, then subsequent...
Eligibility Criteria
Inclusion
- Adults aged 18 years or older at the time of enrollment
- SARS-COV2 positivity by PCR with respiratory failure requiring mechanical ventilation for at least 72 hours
- Prior therapy with antifungals, including prophylaxis, is NOT an exclusion.
Exclusion
- Life expectancy of less than 72 hours as determined by the site investigator.
- Expected to be weaned from mechanical ventilation in next 24 hours
- Care received in any setting other than an intensive care unit (ICU) at the time of enrollment
Key Trial Info
Start Date :
March 9 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
January 13 2023
Estimated Enrollment :
219 Patients enrolled
Trial Details
Trial ID
NCT04818853
Start Date
March 9 2021
End Date
January 13 2023
Last Update
May 14 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The University of Alabama at Birmingham
Birmingham, Alabama, United States, 35233